Tissue-type plasminogen activator (t-PA) is a pivotal enzyme in the mammalian fibrinolytic system. It exerts its action by converting the zymogen plasminogen into the proteolytically active serine protease plasmin, which, in turn, degrades fibrin clots. Because of its affinity for fibrin, t-PA is the prototypic fibrin-specific plasminogen activator (1). This specificity and its lack of antigenicity have made it a powerful tool in the treatment of acute myocardial infarction (2). The t-PA is inactivated by its suicide substrate, plasminogen activator inhibitor-1 (PAI-1) (3). Storage of t-PA in endothelial cells. The t-PA is synthesized and stored in endothelial cells and vascular neurons (4,5). There has been much controversy in the published data regarding the specific endothelial cell vesicle in which t-PA is stored. It has been suggested that because t-PA is often released concomitantly with von Willebrand factor (vWF), both proteins are stored in Weibel-Palade bodies. Emeis et al. (6) demonstrated that this is not necessarily the case. In studies using rat lung homogenates fractionated by See page 961 density gradient centrifugation, particles containing a majority of the t-PA antigen and activity were found at similar densities in sucrose and Nycodenz gradients. The Nycodenz gradient co-localized t-PA granules with vWF containing Weibel-Palade bodies. However, the two proteins fractionated at different densities in sucrose. Using doubleimmunofluorescence staining of human umbilical vein endothelial cells, t-PA and vWF particles did not co-localize (6). Further evidence that t-PA and vWF are stored in separate granules is based on the observation that these proteins are differentially released by specific stimuli. For example, ionomycin-induced vWF release is dosedependent and correlates with the increase in intracellular calcium concentration. In contrast, t-PA is not released until the calcium concentration exceeds a threshold of 500 nM (7). Thus, it appears that t-PA and vWF vesicles fractionate at different densities, do not co-localize by immunofluoroscopy, and can be induced to be released separately. Molecular mechanisms of t-PA release. In vitro studies of t-PA release have revealed much about the signal transduction pathways involved in its release. Early studies revealed that constitutive release of t-PA from the endothelium can be augmented in a dose-and time-dependent manner by protein kinase C (PKC) activation. In PKC-activated cells, cyclic adenosine monophosphate (cAMP) agonists augment t-PA secretion (8). Furthermore, PKC-augmented t-PA secretion is dependent on an increase in t-PA message (9). However, these studies examined t-PA secretion over periods of hours to days, not minutes.
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Subsequently, a cell culture model of t-PA release was developed. In this model, it was found that t-PA is both constitutively secreted and can be released rapidly in a dose-dependent manner in response to agonists such as thrombin, isoproterenol, and prostacyclin. It was discovered that these agonists act in a dose-dependent manner, and preincubation of cells with sodium butyrate or retinoic acid amplifies the response to stimulation with agonists (10) .
Little is known about the precise molecular mechanisms by which bradykinin induces t-PA release. It has been suggested that thrombin and prostacyclin induce t-PA release through independent G-protein-signaling pathways (7, 11) . Prostacyclin and isoproterenol couple G s and likely signal through cAMP, whereas thrombin, which couples G q , likely signals through calcium-dependent pathways. The thrombin receptor couples G 12 , G i , and G q . The G i , which inhibits adenylyl cyclase, and G 12 , which signals through Rho, seem unlikely candidates in facilitating t-PA release. G q , which generates inositol triphosphate through phospholipase C-beta (PLC-beta), inducing intracellular calcium shifts, appears to be a likely downstream target. The G-protein subunits beta and gamma, which also activate PLC-beta, may also be responsible for these calcium effects (12) . Furthermore, coupling of the thrombin receptor to G i may explain the variable effects of pertussis toxin on t-PA release in the presence and absence of calcium (7) . In vivo studies of t-PA release. As alluded to earlier, t-PA release from endothelial cells is an area of much interest, as it is a distinct marker of endothelial function. Studies of in vivo t-PA release have revealed much about the mechanics of this phenomenon, as both endothelial-dependent agonists such as methacholine and endothelial-independent agonists such as isoproterenol induce rapid release of t-PA, independent of effects on vessel wall relaxation (13) . In addition to these agonists, bradykinin was also found to induce t-PA release and increase flow in both the human forearm and coronary artery bed (14, 15) . Bradykinininduced t-PA release is a bradykinin type-2 receptor (B 2 )-mediated phenomenon, as HOE-140, a specific B 2 receptor antagonist, blocks bradykinin-mediated t-PA release. Because B 2 stimulation results in prostacyclin and nitric oxide generation, it was hypothesized that inhibition of synthesis of these products with indomethacin, a nonselective cyclooxygenase inhibitor, and L-N G -monomethyl-L-arginine (L-NMMA), an inhibitor of nitric oxide synthase, would prevent t-PA release from the vascular bed. However, neither indomethacin nor L-NMMA, alone or in combination, inhibited bradykinin-induced t-PA release. This led to the hypothesis that it may be either an endothelial-derived hyperpolarization factor-mediated phenomenon or perhaps a calcium-mediated phenomenon, as the B 2 receptor couples to the G q /PLC-beta/calcium-signaling pathway (16) .
Because bradykinin is rapidly degraded by angiotensinconverting enzyme (ACE), one would anticipate that ACE inhibition would augment bradykinin-induced t-PA. Treatment with quinapril enhanced bradykinin-induced t-PA release in the human forearm, whereas losartan, an angiotensin II type-1 receptor blocker, had no effect. Substance P-mediated t-PA release, however, was not augmented by treatment with quinapril or losartan. Labinjoh et al. (17) suspected that some of the beneficial clinical effects of ACE inhibitors may be the result of enhancement of bradykininmediated t-PA release.
In humans, t-PA release in response to bradykinin or Substance-P is impaired in smokers, both in the coronary vasculature and forearm (18, 19) . Methacholine-induced t-PA release is unchanged in borderline hypertensive subjects (20) . Other conditions associated with impaired endothelial vasodilator function, such as hypercholesterolemia and diabetes, have not been specifically studied for their impact on arterial t-PA release in response to bradykinin or substance P.
In this issue of the Journal, Witherow et al. (21) examined the effects of ACE inhibition on t-PA release in subjects with ischemic cardiomyopathy. The highlight of this study is the extremely robust response to bradykinin in the presence of ACE inhibition; this response was 4.5-fold greater than that seen in subjects without ischemic cardiomyopathy. The authors describe transient t-PA increases that approach those seen when t-PA is administered for acute myocardial infarction. This augmented response may reflect therapeutic effects of ACE inhibition in individuals whose neurohormonal axis has been perturbed by heart failure.
Questions that arise from this work include the effects of bradykinin on the presumably diseased coronary bed of subjects with ischemic cardiomyopathy. The coronary vasculature in these subjects will likely have a greater plaque burden than that seen in the forearm, more local ACE activity, reduced local bradykinin concentrations, and presumably upregulated B 2 receptors. This environment would seem predisposed to an augmented response to ACE inhibition and exogenous bradykinin. Although there was no difference between losartan and placebo in the previous study of normal subjects, angiotensin II may play a larger role in the fibrinolytic balance of patients with heart failure, by stimulating PAI-1 expression. This study has, for the first time, to the best of our knowledge, shown that ACE inhibition augments bradykinin-induced t-PA release in patients with known cardiovascular disease. Although many drugs have been reported to improve endothelial-dependent vasodilation, much less is known about the clinical factors that impair endothelial t-PA release or therapies that restore this important function. Furthermore, it is possible that t-PA release may be a critical aspect of endothelial function in terms of preventing coronary thrombosis. Studies such as Witherow et al. (21) are likely to lead to a more comprehensive perspective of the complexities of endothelial function.
